Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Down 28.2% in October

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 17,100 shares, a decline of 28.2% from the October 15th total of 23,800 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 12,000 shares, the days-to-cover ratio is currently 1.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Lisata Therapeutics in a research note on Wednesday, September 18th.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP grew its stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Trading Up 0.7 %

Shares of NASDAQ:LSTA traded up $0.02 during midday trading on Thursday, reaching $2.81. 3,975 shares of the company were exchanged, compared to its average volume of 13,598. The stock has a market cap of $23.38 million, a PE ratio of -1.11 and a beta of 1.22. The business’s fifty day moving average is $2.97 and its two-hundred day moving average is $3.09. Lisata Therapeutics has a one year low of $2.05 and a one year high of $3.83.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Monday, August 12th. The company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.14. During the same period in the previous year, the company earned ($0.50) earnings per share. As a group, sell-side analysts expect that Lisata Therapeutics will post -2.9 EPS for the current year.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.